Independent reference. Not affiliated with, endorsed by, or speaking for the U.S. Food and Drug Administration.
FDA Medication Tracker

← All approvals · Eye · 2026

Lytenava (bevacizumab-vikg)

The FDA approved Lytenava (bevacizumab-vikg) on July 24, 2026 to treat patients with neovascular (wet) age-related macular degeneration.
Brand name
Lytenava
Generic name
bevacizumab-vikg
FDA approval date
July 24, 2026
Approved use (FDA wording)
To treat patients with neovascular (wet) age-related macular degeneration
Category on this site
Eye

Official sources

Facts only. This site lists what the FDA has approved and what the FDA says each drug is approved for, quoted or closely paraphrased from FDA and openFDA records. It gives no medical advice, no dosing, and no comparisons, and it says nothing about whether a drug is right for anyone. Talk to a licensed clinician about any medication. Records can lag or contain errors; the FDA's own pages are authoritative.